SCHEMBL17830717

SCHEMBL17830717

CC(C)(C)OC(=O)Nc1cccc(CNC(=O)Cn2c(=O)oc3cc(Cl)ccc32)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
POLB P06746 6/20 0.53
TP53 P04637 4/20 0.52
PIK3CB P42338 1/20 0.49
KMT2A Q03164 3/20 0.49
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
THRB P10828 1/20 0.47
MEN1 O00255 1/20 0.46
CBX7 O95931 1/20 0.46
RECQL P46063 1/20 0.46
CDYL2 Q8N8U2 1/20 0.46
CDYL Q9Y232 1/20 0.46
CDY1; CDY1B Q9Y6F8 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16366689 0.86 POLB (0.60) MAPTPOLBTP53PIK3CBKMT2A
SCHEMBL16366687 0.85 POLB (0.59) MAPTPOLBTP53PIK3CBKMT2A
SCHEMBL16366686 0.84 POLB (0.55) MAPTPOLBTP53PIK3CBKMT2A
SCHEMBL17830719 0.80 MAPT (0.61) MAPTPOLBTP53PIK3CBKMT2A
SCHEMBL16366691 0.76 POLB (0.58) MAPTPOLBTP53PIK3CBKMT2A
SCHEMBL17830718 0.75 POLB (0.62) MAPTPOLBTP53KMT2ALMNA
SCHEMBL16366688 0.75 POLB (0.58) MAPTPOLBTP53PIK3CBKMT2A
SCHEMBL17830716 0.74 LMNA (0.53) MAPTPOLBTP53PIK3CBKMT2A
SCHEMBL2541714 0.74 PIK3CB (0.56) MAPTPOLBTP53PIK3CBKMT2A
SCHEMBL16366690 0.73 POLB (0.56) MAPTPOLBTP53PIK3CBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A MAPT 2263/4885POLB 2366/4885TP53 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.